| First Author | Martinez-Campanario MC | Year | 2023 |
| Journal | Nat Commun | Volume | 14 |
| Issue | 1 | Pages | 8316 |
| PubMed ID | 38097578 | Mgi Jnum | J:343548 |
| Mgi Id | MGI:7566759 | Doi | 10.1038/s41467-023-43896-7 |
| Citation | Martinez-Campanario MC, et al. (2023) Atherosclerotic plaque development in mice is enhanced by myeloid ZEB1 downregulation. Nat Commun 14(1):8316 |
| abstractText | Accumulation of lipid-laden macrophages within the arterial neointima is a critical step in atherosclerotic plaque formation. Here, we show that reduced levels of the cellular plasticity factor ZEB1 in macrophages increase atherosclerotic plaque formation and the chance of cardiovascular events. Compared to control counterparts (Zeb1(WT)/Apoe(KO)), male mice with Zeb1 ablation in their myeloid cells (Zeb1(M)/Apoe(KO)) have larger atherosclerotic plaques and higher lipid accumulation in their macrophages due to delayed lipid traffic and deficient cholesterol efflux. Zeb1(M)/Apoe(KO) mice display more pronounced systemic metabolic alterations than Zeb1(WT)/Apoe(KO) mice, with higher serum levels of low-density lipoproteins and inflammatory cytokines and larger ectopic fat deposits. Higher lipid accumulation in Zeb1(M) macrophages is reverted by the exogenous expression of Zeb1 through macrophage-targeted nanoparticles. In vivo administration of these nanoparticles reduces atherosclerotic plaque formation in Zeb1(M)/Apoe(KO) mice. Finally, low ZEB1 expression in human endarterectomies is associated with plaque rupture and cardiovascular events. These results set ZEB1 in macrophages as a potential target in the treatment of atherosclerosis. |
